de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Poster

Novel Azamacrocyclic Conjugates in the Development of “Smart” and Targeted Contrast Agents for MR Imaging

MPG-Autoren
http://pubman.mpdl.mpg.de/cone/persons/resource/persons84084

Mamedov,  I
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons84074

Mishra,  A
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons84137

Pfeuffer,  J
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons84063

Logothetis,  NK
Department Physiology of Cognitive Processes, Max Planck Institute for Biological Cybernetics, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Mamedov, I., Mishra, A., Pfeuffer, J., & Logothetis, N. (2005). Novel Azamacrocyclic Conjugates in the Development of “Smart” and Targeted Contrast Agents for MR Imaging. Poster presented at 4th Annual Meeting of the Society for Molecular Imaging (SMI 2005), Köln, Germany.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0013-D473-4
Zusammenfassung
Smart MR contrast agents exhibit modulation of their relaxivity by specific physiological or biochemical trigger-events, while targeted MR contrast agents are envisioned to deliver the large gadolinium chelates into the target tissue. In an effort to develop novel smart and targeted MR contrast agents, the series of the DO3A based multifunctional chelating agents with the variable length of the side chain has been synthesized. They serve as valuable multipurpose precursors for contrast agents based on gadolinium chelates in the design of relaxometric MR probes. The presence of the amino group in the side chain of the macrocycle allows for conversion into various functional groups (aminophosponates, aminocarboxylates, etc.) or for conjugation with different biomolecules, dyes, and polymers. Choice of the functional groups depends on the further application of the compounds. A series of gadolinium chelate complexes based on the compounds 1a-d were developed, in order to change relaxivity in magnetic resonance experiments dynamically with Ca2+ concentration. The potential of Ca2+ MR imaging in neuroscience is evident in the intensive efforts to design gadolinium complexes that can act as calcium-dependent MRI contrast agents. Different lengths of the phosphonate side chains are expected to lead to different binding constants of the phosphonate - gadolinium bonds. The latter property can be exploited for fine-tuning the sensitivity of the agent to calcium ion concentration. The sensitivity of the contrast agents for changes in Ca2+ concentrations increased with the chain length of the phosphonate functions, specifically for compound 1d (n=4) the range of Ca2+ concentration is compatible with extracellular physiological conditions. For the purpose of targeted MRI, two macrocyclic bioconjugates were synthesized. A conjugate 2 of Gd-DO3A-EA with biotin was synthesized for targeted imaging in an antibodyavidin system. Mixture of 2 and avidin (4:1) showed 54 relaxivity enhancement for r1 and 311 for r2 relative to the unbound 2. A macrocyclic conjugate 3 of Gd-DO3A-EA with FITC was designed to track cellular binding and internalization by both fluorescence detection and MR imaging. The compound did not show cytotoxicity after treatment up to 50 μM for 24 hrs (NIH-3T3 cells, PI assay). Fluorescence microscopy of living cells displayed detectable internalisation.